moneyheap
BAX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Baxter International Inc. (BAX) stock moving?
Baxter reported a Q3 2026 beat on October 29: adjusted EPS of $0.58 versus a $0.52 estimate and sales of $2.976B versus $2.908B, with 5% organic growth across all segments. The company raised FY2026 guidance, with adjusted EPS now $2.05-$2.15 and sales of $11.694B-$11.806B, both above consensus. It also completed a $600M tender offer that retired $864M of debt, and year-to-date free cash flow reached $705M. The stock fell about 7.7% on October 29 to $23.50 despite the beat, likely because adjusted EPS declined 16% year over year on a higher tax rate. It then recovered to $26.42 by November 10, a gain of roughly 12% from the low. Analyst reactions are mixed: Wells Fargo raised its target to $25 (Equal-Weight), JP Morgan cut its target to $25 (Neutral), and Barclays kept an Underweight rating with a $23 target. The current price sits above all three targets, which limits near-term upside on consensus views. The 30-day price data shows a volume spike on earnings (15.7M shares) that has since faded to about 3.8M shares, with the stock trading between $25.5 and $26.5 in the last week.
News behind the analysis
- Barclays Maintains Underweight on Baxter International, Raises Price Target to $23Barclays kept its Underweight rating on Baxter and raised its price target to $23, still below the recent close of $26.42.
- Baxter International Updates Full-Year 2026 Guidance and Reports Debt ReductionBaxter raised its full-year 2026 sales growth and adjusted diluted EPS guidance and completed a $600 million cash tender offer to retire debt.
- JP Morgan Maintains Neutral on Baxter International, Lowers Price Target to $25JP Morgan kept its Neutral rating and lowered its price target to $25 after the third-quarter report.
- Wells Fargo Maintains Equal-Weight on Baxter International, Raises Price Target to $25Wells Fargo kept its Equal-Weight rating and raised its price target from $23 to $25.
- Why Is Baxter Stock Trading Lower on Thursday?Baxter topped Q3 consensus with $0.58 adjusted EPS and $2.976B in sales, and raised fiscal 2026 profit and revenue guidance above Wall Street forecasts.
- Baxter Intl Q3 2026 Earnings Call TranscriptBaxter's management discussed its third-quarter 2026 results, which reported on Thursday, Oct 29.
- Baxter Reports Third-Quarter 2026 ResultsBaxter reported growth across all global segments and divisions in the third quarter of 2026.
- Baxter International Raises FY2026 Adj EPS Guidance from $1.95-$2.15 to $2.05-$2.15 vs $2.05 Est; Raises FY2026 Sales Guidance from $11.581B-$11.694B to $11.694B-$11.806B vs $11.619B EstBaxter narrowed its adjusted EPS guidance to $2.05-$2.15, above the $2.05 estimate, and raised FY2026 sales guidance to $11.694B-$11.806B against a $11.619B estimate.
- Baxter Intl Q3 Adj. EPS $0.58 Beats $0.52 Estimate, Sales $2.976B Beat $2.908B EstimateBaxter's third-quarter adjusted EPS of $0.58 beat the $0.52 estimate and sales of $2.976B beat the $2.908B estimate.
About Baxter International Inc.
Baxter International is a Deerfield, Illinois–based medtech company that makes products hospitals use every day, including IV pumps, IV fluids and injectable drugs, and surgical products. It has slimmed down in recent years, selling its kidney care business (now Vantive) in 2025. It is now centred on hospital infusion and surgical products, and is in a turnaround under CEO Andrew Hider, with cost-cutting and quality fixes after an FDA warning letter.
How it makes money
Baxter sells medical equipment, disposables and drugs mainly to hospitals and other care sites, with total sales of roughly $11.6 billion a year (approximate). Its Medical Products and Therapies segment is a bit over half of sales, about $2.1 billion a quarter (approximate). That segment covers infusion pumps and IV sets, advanced surgery products such as hemostats and sealants, and Hillrom-derived hospital beds and monitoring equipment. A second segment covering injectable drugs, IV fluids and pharmacy drug compounding brings in about $1.7 billion a quarter (approximate). Much of the revenue repeats, because hospitals keep buying fluids and disposables.
What usually moves BAX
- Hospital procedure volumes and capital spending
- Gross margin trends, including manufacturing costs and tariffs
- FDA quality issues and product recalls
- Progress on paying down debt and cutting costs
- IV fluid supply and pricing